Suppr超能文献

应用高通量焦磷酸测序技术进行线粒体疾病的诊断。

Diagnosis of mitochondrial disorders applying massive pyrosequencing.

机构信息

Consultorio de Neurogenética, Centro Universitario de Neurología JM Ramos Mejía, Buenos Aires, Argentina.

出版信息

Mol Biol Rep. 2012 Jun;39(6):6655-60. doi: 10.1007/s11033-012-1471-9.

Abstract

Mitochondrial disorders are a frequent cause of neurological disability affecting children and adults. Traditionally, molecular diagnosis of mitochondrial diseases was mostly accomplished by the use of Sanger sequencing and PCR-RFLP. However, there are particular drawbacks associated with the use of these methods. Recent multidisciplinary advances have led to new sequencing methods that may overcome these limitations. Our goal was to explore the use of a next generation sequencing platform in the molecular diagnosis of mitochondrial diseases reporting our findings in adult patients that present with a clinical-pathological diagnosis of a mitochondrial encephalomyopathy. Complete genomic sequences of mitochondrial DNA were obtained by 454 massive pyrosequencing from blood samples. The analysis of these sequences allowed us to identify two diagnostic pathogenic mutations and 74 homoplasmic polymorphisms, useful for obtaining high-resolution mitochondrial haplogroups. In summary, molecular diagnosis of mitochondrial disorders could be efficiently done from readily accessible samples, such as blood, with the use of a new sequencing platform.

摘要

线粒体疾病是一种常见的神经功能障碍病因,可影响儿童和成人。传统上,线粒体疾病的分子诊断主要通过桑格测序和 PCR-RFLP 来完成。然而,这些方法的使用存在一些特殊的缺点。最近的多学科进展带来了新的测序方法,可能克服这些局限性。我们的目标是探讨下一代测序平台在分子诊断线粒体疾病中的应用,报告我们在成年患者中的发现,这些患者的临床表现为线粒体脑肌病。通过血液样本的 454 焦磷酸测序获得线粒体 DNA 的完整基因组序列。对这些序列的分析使我们能够识别出两个诊断致病性突变和 74 个同质多态性,这些突变和多态性有助于获得高分辨率的线粒体单倍群。总之,线粒体疾病的分子诊断可以通过使用新的测序平台,从血液等易于获取的样本中高效完成。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验